Successful treatment of myalgic encephalomyelitis/chronic fatigue syndrome using hydrogen gas: four case reports

Medical Gas Research, Journal Year: 2023, Volume and Issue: 14(2), P. 84 - 86

Published: Sept. 8, 2023

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is characterized by unexplained and malaise that persist for more than 6 months with neuropsychiatric symptoms, including slight fever, headache, weakness, impaired thinking, depression.[1,2] The onset severity of these symptoms vary reduce the quality life as well social, occupational, personal activities those affected, some becoming bedridden.[1,2] number ME/CFS patients in United States estimated to be between 836,000 2.5 million.[3] Although it currently remains unclear whether there are objective biological abnormalities ME/CFS, recent neuroimaging, blood marker analyses, energy metabolism mitochondrial studies detected patients.[4] may caused activation immune system, both within outside brain, which induces release inflammatory cytokines. presumed cause central autonomic nervous systems, systemic metabolism, system also involve oxidative nitrosative stress.[4,5,6] Dysfunctions related structure function mitochondria.[7,8,9,10] Molecular hydrogen (H2) a gaseous molecule selectively scavenges reactive oxygen nitrogen species strong oxidizing power, namely, hydroxyl radicals (·OH) peroxynitrite, respectively.[11,12] H2 easily crosses blood-brain barrier membranes, reaches mitochondria, protects cells from ·OH-induced cell damage.[11,12] A literature review revealed attenuated acute or chronic animals healthy subjects.[13] We reported anti-fatigue effects involved protection ameliorate pathogenesis ME/CFS.[13] Therefore, we conducted this case study test hypothesis examining efficacy gas inhalation four ME/CFS. Case 1: herein present 58-year-old male patient who successfully responded therapy. Canadian Consensus Criteria (CCC) based on score 21 (no symptoms: 0, mild: 1, moderate: 2, severe: 3), typical such post-exertional fatigue, sleep disturbance, pain, chemical intolerance.[14] each symptom total (a maximum 63) used establish improve worsen.[14] To evaluate patient, adopted medical interview CCC recorded every two weeks because no accurate method substances show against other patients' symptoms. developed extreme April 2012 had difficulties thinking clearly concentrating. He visited various hospitals an attempt diagnose treat but was unsuccessful. National Center Neurology Psychiatry (NCNP) 2019. Many examinations were performed subjective met criteria CCC. Various treatments approximately years, inhaled 6–7% (2 L/min, MHG-2000α, MiZ Company Limited, Kamakura, Japan) produced water electrolysis June 2021 November 3–5 hours per day. Severity scores before after treatment shown Table 1 Figure 1.Figure 1:: Changes "brain fog" inhalation.Note: has been inhaling Each CCC, calculated.[ 14 ] vaccinated COVID-19 at 8 11, vaccination exacerbated However, recovered pre-vaccination level inhalation. CCC: Criteria; COVID-19: coronavirus disease 2019; H2: molecular hydrogen; ME/CFS: myalgic syndrome.Table inhalationThe decreased 29 points 23 weeks, confirming significant attenuation severe intense exertion. amelioration headaches, muscle joint poor concentration, recurrent sore throat noted. Further improvements observed weeks. Severe aches following increased intensity exercise markedly alleviated. Weight gain noted flow feet, shortness breath exertion sensitivity sound decreased. not reflected score, reduced; 15. 16 significantly different weeks; however, days without increased. 2019 (COVID-19) 11. Five first vaccination, temporarily worsened, week 10 16. Eight second (12 inhalation), worsened 27. vigorous inhalation, levels returned temporary, same while daily activity ready rehabilitative training return work. since his condition yet stabilized, only able perform individual once three days. Nevertheless, steady recovery observed. still occurred, recover resting few gas. After 18 he living, housework, light work, going out neighborhood, physical recurred completely resolved. Since greater range 20 treatment, took small trip. felt tired fell asleep returning home, days, suggesting fatigue-attenuating Furthermore, 13 during week. Cases 2–4: Due conducted. provided type inhaler referred NCNP. assessed twice, 3 9 recording general self-scoring 2: 43-year-old woman diagnosed probable NCNP 2017 attempted treatments, did respond well. Prior she unable maintain standing, erect, seated postures due reductions upper lower extremity trunk functions. spent most her time bed day wheelchair indoor mobility. She exhibited malaise, exertion, disturbance bradycardia, hypotension, testing end August early 2021. Sleep headaches migraines, occurred several times day, Nine later, migraines continued ameliorated 3: An 18-year-old 2020 bed. began 5 October Approximately decrease improved bowel movements, motivation. At sleeping much activity, tired. 4: man fibromyalgia pains, memory, tinnitus, fog". headache pain ameliorating use analgesics. In addition, improved. Substances attenuate being developed. Clinical investigated efficacies antibody drug rituximab, nicotinamide adenine dinucleotide hydrogen, coenzyme Q10, acetyl L-carnitine found they ineffective their limited.[15,16,17,18] development therapeutic curative rather symptomatic needed. study, examined 2 years ago therapies, treated throat, abnormal body temperature, sound. 2–4 attempts. disturbances, motivation, brain fog all patients. These cases results infection respiratory 2. resolve 2–3 continue have "sequelae" initial infection. "sequelae," termed "long COVID" "post similar ME/CFS.[19,20] despite similarities, trigger Botek et al.[21] recently single-blind randomized trial 50 functions phase further large-scale needed, if assume develops via mechanism our supported findings conclusion, self-assessments clinical form controlled trial, limitations results. obtained suggest potential needed agent underlying action. Ethical approval waived research study. Written informed consent subjects publication data included article. authors would like thank Dr. Takashi Yamamura advice throughout submission report. Mr. Rei Takusagawa help preparing data. SH, YI, BS, FS employees Limited. YT declared absence any commercial financial relationships construed conflict interest. Open access statement: This open journal, articles distributed under terms Creative Commons AttributionNonCommercial-ShareAlike 4.0 License, allows others remix, tweak, build upon work non-commercially, long appropriate credit given new creations licensed identical terms.

Language: Английский

---

Unmasking Pandemic Echoes: An In-Depth Review of Long COVID’s Unabated Cardiovascular Consequences beyond 2020

Diagnostics, Journal Year: 2023, Volume and Issue: 13(21), P. 3368 - 3368

Published: Nov. 2, 2023

At the beginning of 2020, coronavirus disease 2019 (COVID-19) emerged as a new pandemic, leading to worldwide health crisis and overwhelming healthcare systems due high numbers hospital admissions, insufficient resources, lack standardized therapeutic protocols. Multiple genetic variants severe acute respiratory syndrome 2 (SARS-CoV-2) have been detected since its first public declaration in some them being considered concern (VOCs) corresponding several pandemic waves. Nevertheless, growing number COVID-19 patients are continuously discharged from hospitals, remaining symptomatic even months after their episode infection. Long or ‘post-acute syndrome’ characterized by variability clinical manifestations ranging cardiorespiratory neurological symptoms such chest pain, exertional dyspnoea cognitive disturbance psychological disturbances, e.g., depression, anxiety sleep with crucial impact on patients’ quality life. Moreover, COVID is viewed cardiovascular risk factor capable modifying trajectory current future diseases, altering prognosis. Therefore, this review we address definitions pathophysiology, focus manifestations. Furthermore, aim mechanisms chronic cardiac injury variety sequelae observed recovered patients, addition potential role clinics medical management condition. We will further research for better understanding actual directions.

Language: Английский

---

An update of the literature about rehabilitation tools used in the treatment of COVID-19-related disabilities: a systematic review of literature

Panminerva Medica, Journal Year: 2024, Volume and Issue: 66(3)

Published: June 6, 2024

INTRODUCTION: The role of rehabilitation during and after the COVID-19 pandemia was influenced by progressive acquisition knowledge on pathology with adaptation rehabilitative instruments to heterogeneous impairments patients. aim this systematic review is describe effects tools applied in last three years different phases disease.EVIDENCE ACQUISITION: A literature search MEDLINE (PubMed), Scopus Physiotherapy Evidence Database (PEDro) conducted. 2994 participants were included review: 1225 patients for acute-COVID, 1331 post-COVID, 438 long-COVID.EVIDENCE SYNTHESIS: Of initial 907 hits only 45 randomized controlled trials included. Cochrane library assessment tool used evaluate risk bias. selected studied respiratory alone or association exercises, tele-rehabilitation, endurance training, virtual reality, electrostimulations settings infection evaluation clinical, quality life impairment outcome measures.CONCLUSIONS: All rehabilitations based experts' opinion rules good clinical practice, pandemic period. Despite heterogeneity studies, measures small sample sizes, pulmonary rehabilitation, tele-rehabilitation low/moderate intensity aerobic exercises seemed improve outcomes at short (8 weeks) mean time (2 months) treatments all infection.

Language: Английский

---

Early Hydrogen–Oxygen Gas Mixture Inhalation in Patients with Aneurysmal Subarachnoid Hemorrhage (HOMA): study protocol for a randomized controlled trial

Trials, Journal Year: 2024, Volume and Issue: 25(1)

Published: June 11, 2024

Abstract Background Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening neurosurgical emergency with high mortality rate. Delayed cerebral ischemia (DCI) and vasospasm (CVS) are delayed products of early brain injury (EBI), which may constitute the principal determinant an unfavorable patient prognosis. Consequently, mitigation DCI CVS assumes paramount significance in pursuit enhanced outcomes. However, except for oral nimodipine, there no effective therapy available current guideline. Hence, exigency arises to proffer novel treatment paradigms. The diversity hydrogen therapeutic targets has been largely reported basic research, unveiling its latent capacity ameliorate EBI aSAH patients. Methods Early H ydrogen– O xygen Gas M ixture I nhalation Patients Subarachnoid Hemorrhage (HOMA), single-center, prospective, open-labeled, randomized controlled clinical trial, endeavors evaluate efficacy safety hydrogen–oxygen gas mixture inhalation A cohort 206 patients will be either group (8 h per day, 3 L/min, concentration 67%, oxygen 33%) or within 72 after treated 7 days ICU ward. primary outcomes incidence during hospitalization. Discussion HOMA aims effectiveness preventing improving Notably, this first large-scale trial Given that Chinese population represents significant portion global increasing stroke due aging, optimizing care vital. challenges outcomes, initiating more prospective trials essential. Recent research shown hydrogen’s potential, aligning aSAH, driving our exploration therapy’s mechanisms post-aneurysm rupture damage. Ethics dissemination protocol study was approved by Committee Beijing Tiantan Hospital, Capital Medical University (KY 2022–020-02). All results present published peer-reviewed journals presented at relevant conferences. Trial registration ClinicalTrials.gov NCT05282836. Registered on March 16, 2022.

Language: Английский

---

H ₂ inhalation therapy in patients with moderate COVID-19 (H ₂ COVID): a prospective ascending-dose phase I clinical trial

Antimicrobial Agents and Chemotherapy, Journal Year: 2024, Volume and Issue: 68(8)

Published: July 17, 2024

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome 2 (SARS-CoV-2), has triggered a serious global health crisis, resulting in millions of reported deaths since its initial identification China November 2019. disparities immunization access emphasize urgent need for ongoing research into therapeutic interventions. This study focuses on potential use molecular dihydrogen (H2) inhalation as an adjunctive treatment COVID-19. H2 therapy shows promise inhibiting intracellular signaling pathways associated with inflammation, particularly when administered early conjunction nasal oxygen therapy. phase I study, characterized open-label, prospective, monocentric, and single ascending-dose design, seeks to assess safety tolerability procedure individuals confirmed SARS-CoV-2 infection. Employing 3 + includes three exposure durations (target durations): 1 day (D1), days (D2), 6 (D3). We concluded that maximum tolerated duration is at least days. Every patient showed clinical improvement excellent tolerance To best our knowledge, this trial first establish inhaling mixture (3.6%) N2 (96.4%) hospitalized COVID-19 patients. original device method employed ensure absence explosion risk. encouraging outcomes observed 12 patients included justify further exploration through larger, controlled trials. registered ClinicalTrials.gov NCT04633980.

Language: Английский

---